Kodiak Sciences Q2 2024 Earnings Report

Reported business highlights and financial results for the quarter ended June 30, 2024.

Key Takeaways

Kodiak Sciences reported a net loss of $45.1 million for the second quarter of 2024, with cash and cash equivalents of $219.2 million at the end of the quarter. The company is focusing on advancing its clinical programs for tarcocimab, KSI-501, and KSI-101, and has strengthened its executive team.

GLOW2 Phase 3 study of tarcocimab in diabetic retinopathy continues to enroll.

DAYBREAK Phase 3 study of tarcocimab and KSI-501 is actively enrolling patients.

APEX Phase 1b study of KSI-101 in patients with macular edema secondary to inflammation is now enrolling patients.

New leadership appointments were made to strengthen the executive team.

Previous year: -$1.53

-43.8%

Net loss per common share

-$0.86